Introduction: Antibiotic treatment failure contributes to the economic and humanistic burdens of community-acquired pneumonia (CAP) by increasing morbidity, mortality, and healthcare costs. This study compared treatment failure rates of levofloxacin with those of other antibiotics in a large US sample. Methods: Medical and pharmacy claims in the nationally representative SDI database were used to identify adults with a new outpatient diagnosis of CAP receiving a study antibiotic (levofloxacin, amoxicillin/clavulanate, azithromycin, moxifloxacin) between September 1, 2005 and March 31, 2008. Treatment failure was defined as ≥1 of the following events ≤30 days after index date: a refill for the index antibiotic after completed days of therapy, a different antibiotic dispensed >1 day after the index prescription, or hospitalization with a pneumonia diagnosis or emergency department visit >3 days postindex. Cohorts were propensity score matched for demographic and clinical characteristics. Treatment failure rates were compared between pairs of cohorts for the full sample and for highrisk patients (age ≥65 and/or on Medicaid).
INTRODUCTION
Community-acquired pneumonia (CAP) is a major cause of morbidity, mortality, and healthcare resource expenditure. 1 In the US in 2006, the most recent year for which data are available, pneumonia and influenza were the eighth leading causes of death. 2 Pneumonia accounted for 4.2 million ambulatory care visits, including 1.5 million emergency department visits, 3 and was among the six most common reasons for hospitalization with an average length of stay of 5.1 days. 4 The burden of CAP is particularly significant in the elderly, 5 among whom it is the sixth leading cause of death in the US. 6 CAP is most often caused by bacterial pathogens including Streptococcus pneumoniae, atypical organisms (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp.), Hemophilus influenzae, and gram-negative rods; 7 antibiotics are standard treatment for CAP. 5 While the efficacy of antimicrobial therapy in CAP is established, authors of a 2009 Cochrane review concluded that data from well-designed clinical studies are insufficient to make evidencebased recommendations for choosing among antibiotics for the treatment of CAP. 5 The need for a stronger evidential foundation for making treatment decisions has contributed to inconsistencies among CAP treatment recommendations and guidelines and provoked calls for research directed at specific topics to inform clinical practice. 1 Among the gaps in the evidence base regarding antibiotics for CAP is information on comparative rates of treatment failure, defined as a clinical condition with inadequate response to antimicrobial therapy. 8 Treatment failure, which results in persistence or progression of infection, contributes significantly to the economic and humanistic burdens of CAP by increasing risk of morbidity and mortality as well as healthcare costs. [9] [10] [11] In a 2005-2006 study conducted in a US regional managed care organization, the mean direct medical costs per case of CAP management were $493 for successful treatment and $3019 for treatment failure, which was operationalized as a second antibiotic course, follow-up emergency room presentation, or hospitalization for CAP within 28 days of the index visit. 12 The incidence of treatment failure in patients with CAP is not definitively established, but estimates range from approximately one in ten 10, 13, 14 to one in five patients. 15 
MATERIALS AND METHODS

Data Source
Data for this retrospective, observational, cohort study were extracted from SDI's Health Insurance Portability and Accountability Act The medical claims database, established in 1999, includes more than 600,000 annual claims (CMS-1500 forms) containing diagnosis and visit information and represents activity of more than 450,000 physicians per month. This study was exempt from institutional review board approval as it was retrospective, did not involve an intervention, and utilized anonymized data.
Sample
The study included patients ≥18 years old given a primary or secondary diagnosis of pneumonia (based on CMS-1500 medical claims) ( 
Endpoints and Data Analyses
The primary outcome of interest was the treatment failure rate. Treatment failure was defined, in a manner consistent with the medical literature, 6,10-12,15 as ≥1 of the following events 
Propensity scores (predicted probabilities)
were estimated from each of the three logistic regression models, and levofloxacin patients were then matched 1:1 by propensity score to patients with the comparator antibiotic using nearest-neighbor matching within a predefined caliper. Treatment failure rates were compared using Bowker's test for paired observations. The third method compared treatment failure rates in the propensity score-matched treatment cohorts using logistic regression analyses. Odds ratios (OR) for the likelihood of treatment failure with each comparator antibiotic versus levofloxacin and 95% CIs were calculated.
The analyses described above, which were done in the full patient sample, were also conducted for a subset of patients considered to be at high risk for treatment failure. The highrisk subset was defined as being ≥65 years old and/or on Medicaid. 16 In both the sample as a whole and the high- 
RESULTS
Sample Characteristics
Of 26.4%, P<0.05) (Figure 3) . No other significant differences were found in propensity scorematched treatment failure rates in either the full sample or the high-risk subset (Figure 3 ).
Adjusted ORs for Treatment Failure, Propensity
Score-Matched Samples
Patients treated with azithromycin were 38% more likely to experience treatment failure 0 5 10 Moxi oxacin, 24.3% n=325 Figure 2 . Unadjusted treatment failure rates in the full sample and the high-risk subset. *P<0.05 vs. levofloxacin. Table 3 . Reasons for treatment failure. than patients treated with levofloxacin in the estimates from the logistic regressions on the full propensity score-matched sample (adjusted OR 1.38; 95% CI: 1.14, 1.67). In the high-risk subset, patients treated with azithromycin were 61% more likely to experience treatment failure than patients treated with levofloxacin (adjusted OR 1.61; 95% CI: 1.22, 2.13). No other significant differences were found in treatment failure rates from the logistic regressions on the propensity score-matched sample (Figure 4 ).
DISCUSSION
Treatment failure in CAP is associated with heightened risk of morbidity and mortality and increased healthcare costs. 9-11 While previous research suggests that initial treatment with fluoroquinolones protects against treatment failure, 10,11 little is known about how antibiotics compare with respect to treatment failure rates.
In this claims analysis involving nearly 4000 patients with newly diagnosed CAP, treatment failure was significantly less likely when levofloxacin was given as an initial antibiotic than when azithromycin was given. In analyses involving propensity score-matched data, the odds of treatment failure were 38% greater with azithromycin than levofloxacin. The benefit of levofloxacin over azithromycin with respect to treatment failure was particularly marked in high-risk patients (ie, those ≥65 years old and/or on Medicaid), among whom the odds of treatment failure were 61% greater with azithromycin than levofloxacin. Treatment failure rates were lower with levofloxacin than azithromycin in the sample as a whole and in high-risk patients despite the older age, on average, of the levofloxacin cohort and the tendency of the levofloxacin cohort to have a greater comorbidity burden.
These findings are consistent with the previous observation that initial treatment of CAP with fluoroquinolones, compared with other guidelines-concordant antibiotics, is linked to a reduced risk of treatment failure. 10, 11 The results of this study are also consistent with The reason for the lower treatment failure rates with levofloxacin compared with azithromycin (and with macrolides generally in the study reported above) 15 In the current study, the benefit of levofloxacin over azithromycin with respect to treatment failure was manifested both in the unadjusted data and in the propensity score- The results of this study show that the treatment failure rate tended to be lower in the levofloxacin group compared with the amoxicillin/clauvulanate group or the moxifloxacin group although the differences were not statistically significant.
